Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study
详细信息 查看全文
- 作者：Amelia Ruffattia ; amelia.ruffatti@unipd.it" class="auth_mail" title="E-mail the corresponding author ; Maria Favaroa ; Ariela Hoxhaa ; Alessandra Zambonb ; Piero Marsonc ; Teresa Del Rossa ; Antonia Calligaroa ; Marta Tonelloa ; Giovanni B. Nardellib
- 关键词：LMWH ; low molecular weight heparin ; LDA ; low dose aspirin ; APS ; antiphospholipid antibody syndrome ; IVIG ; intravenous immunoglobulins ; aPL ; antiphospholipid antibodies ; LAC ; lupus anticoagulant ; HELLP ; hemolysis elevated liver enzymes low platelets ; aCL ; anticardiolipin antibodies ; a-β2GPI ; anti-β2Glycoprotein I antibodies
- 刊名：Journal of Reproductive Immunology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：115
- 期：Complete
- 页码：14-19
- 全文大小：91 K
文摘
- •
Conventional treatments fail in about 20% of antiphospholipid syndrome pregnancies.
- •
Therapy for high-risk antiphospholipid syndrome pregnancies is not yet established.
- •
Apheresis plus intravenous immunoglobulins were evaluated as a second-line therapy.
- •
The combined therapy outlined here led to a high birth rate and no side-effects.